Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Micro Therapeutics, Inc. was a pioneering medical device company specializing in the development of minimally invasive technologies for the treatment of neurovascular and peripheral vascular diseases. The company's flagship product, the Onyx Liquid Embolic System, revolutionized the treatment of brain arteriovenous malformations (bAVMs) by providing a non-adhesive, liquid embolic agent that allows for controlled delivery and deep penetration into vascular lesions. Beyond embolics, the company offered a comprehensive suite of access products, including the SilverSpeed guidewires and Rebar microcatheters, designed to navigate the complex vasculature of the brain. Founded in 1993 and headquartered in Irvine, California, Micro Therapeutics became a leader in the interventional neuroradiology market. The company was acquired by ev3 Inc. in 2006, and its technology now forms a core component of Medtronic's neurovascular portfolio.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Micro Therapeutics.